Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy

Prevalence of Chronic Kidney Disease in US Adults with Undiagnosed Diabetes or Prediabetes

(2010) L. C. Plantinga et al.   Clinical Journal of the American Society of Nephrology

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

(2010) Silke Retlich et al.   CLINICAL PHARMACOKINETICS

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

(2010) Alokesh Duttaroy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

(2009) Mark Kirby et al.   CLINICAL SCIENCE

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

(2008) R CHRISTOPHER et al.   CLINICAL THERAPEUTICS

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS